uPAR-PET/MRI in Glioblastoma Multiforme

• Status: Unknown status
• Trial end date: 2020-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate the applicability of urokinase plasminogen activator receptor (uPAR) Positron Emission Tomography (PET) / MRI molecular imaging of glioblastoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Rigshospitalet, Denmark

Criteria

Inclusion Criteria:

• Patients where imaging with MRI or CT is suspicious of having glioblastoma multiforme, and patients, and who is referred for stereotactic biopsy, chemotherapy or surgery

• The participants must be capable of understanding and giving full informed written consent

• age above 18 years

Exclusion Criteria:

• Pregnancy

• Lactation/breast feeding

• Age above 85 years old

• Weight above 140 kg

• Known allergy towards 68Ga-NOTA-AE105